Eledon Pharmaceuticals (ELDN) Cash from Financing Activities (2013 - 2025)

Eledon Pharmaceuticals (ELDN) has 11 years of Cash from Financing Activities data on file, last reported at $53.7 million in Q4 2025.

• Quarterly Cash from Financing Activities fell 33.02% year-over-year to $53.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $53.8 million (down 59.7% YoY) and the FY2025 annual result came in at $53.8 million, down 59.7% from the prior year.
• Cash from Financing Activities improved to $53.7 million in Q4 2025, from $115000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $80.2 million in Q4 2024 to a low of -$450000.0 in Q1 2021.
• A 3-year average of $23.4 million and a median of $2.7 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2021 — Cash from Financing Activities tumbled 108.67% — and 2025, when it soared 11400.0%.
• Tracing ELDN's Cash from Financing Activities over 3 years: stood at $1000.0 in 2021, then jumped by 8016600.0% to $80.2 million in 2024, then tumbled by 33.02% to $53.7 million in 2025.
• The last three Cash from Financing Activities figures came in at $53.7 million (Q4 2025), $115000.0 (Q1 2025), and $80.2 million (Q4 2024), per Business Quant data.